{"id":"folfirinox-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Anorexia"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"FOLFIRINOX is a combination chemotherapy regimen that includes oxaliplatin, leucovorin, 5-fluorouracil, and irinotecan. This combination works by inhibiting DNA replication and function in rapidly dividing cancer cells, ultimately leading to cell death.","oneSentence":"FOLFIRINOX is a chemotherapy regimen that combines four different drugs to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:24.526Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"},{"name":"Locally advanced pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT07477418","phase":"PHASE1, PHASE2","title":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","status":"NOT_YET_RECRUITING","sponsor":"University of Vermont","startDate":"2026-12","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms","enrollment":10},{"nctId":"NCT04808323","phase":"PHASE1","title":"MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-17","conditions":"Rectal Adenocarcinoma","enrollment":22},{"nctId":"NCT07467434","phase":"","title":"FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Rectal Cancer, Synchronous Liver Metastases, Antineoplastic Combined Chemotherapy Protocols","enrollment":550},{"nctId":"NCT04472910","phase":"NA","title":"GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-21","conditions":"Resectable Pancreatic Cancer","enrollment":84},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT07191418","phase":"NA","title":"Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Roberto Valente","startDate":"2026-03","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":178},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT04683315","phase":"PHASE2","title":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-04-01","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT06850623","phase":"PHASE2","title":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"EXACT Therapeutics AS","startDate":"2025-06-19","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":25},{"nctId":"NCT05065801","phase":"PHASE2","title":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2022-01-11","conditions":"Metastatic Pancreatic Cancer","enrollment":162},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT02021422","phase":"PHASE1","title":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2013-12","conditions":"Pancreas Cancer","enrollment":13},{"nctId":"NCT05475366","phase":"NA","title":"Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-12-12","conditions":"Carcinoma, Pancreatic Ductal, Prognosis","enrollment":85},{"nctId":"NCT07407231","phase":"NA","title":"Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)","status":"RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-09-01","conditions":"Locally Advanced Pancreatic Cancer","enrollment":18},{"nctId":"NCT06122480","phase":"NA","title":"Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-05-21","conditions":"Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease","enrollment":5},{"nctId":"NCT07408505","phase":"NA","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-20","conditions":"Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome","enrollment":56},{"nctId":"NCT05466799","phase":"PHASE2","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OncoSil Medical Limited","startDate":"2023-04-26","conditions":"Locally Advanced Pancreatic Cancer","enrollment":88},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT03983057","phase":"PHASE2","title":"Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":392},{"nctId":"NCT06615830","phase":"","title":"Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Prof. Dr. med. Dres. h.c. Jan Schmidt, MME","startDate":"2026-06-01","conditions":"Pancreas Neoplasms, Pancreatic Neoplasms, Pancreatic Cancer Metastatic","enrollment":185},{"nctId":"NCT02959879","phase":"PHASE2","title":"Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-03-01","conditions":"Resectable Pancreatic Duct Adenocarcinoma","enrollment":153},{"nctId":"NCT00208260","phase":"PHASE2, PHASE3","title":"Intensified Chemotherapy in CRC After Resection of Liver Metastases","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2004-04","conditions":"Colorectal Cancer, Liver Metastases, Chemotherapy","enrollment":124},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT06203821","phase":"PHASE1","title":"Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Aram Hezel","startDate":"2026-09-01","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT00556413","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":42},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06574620","phase":"NA","title":"Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-11-28","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT07340567","phase":"PHASE3","title":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-01","conditions":"Colorectal Cancer","enrollment":2450},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT03322995","phase":"PHASE2","title":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2018-06-21","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT03991962","phase":"PHASE2","title":"Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2019-09-24","conditions":"Pancreatic Cancer","enrollment":28},{"nctId":"NCT07280377","phase":"PHASE1, PHASE2","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","status":"RECRUITING","sponsor":"Oncolytics Biotech","startDate":"2021-10-27","conditions":"Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic","enrollment":122},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT04570943","phase":"PHASE2","title":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-06-16","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":103},{"nctId":"NCT06402864","phase":"PHASE3","title":"Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-26","conditions":"Adult With Intermediate Low or Mid Rectal Adenocarcinoma","enrollment":212},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT07243288","phase":"","title":"Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-01-09","conditions":"Pancreatic Cancer, MeSH Term-Pancreatic Cancer, Adult)","enrollment":400},{"nctId":"NCT07226154","phase":"","title":"Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT05630183","phase":"PHASE2","title":"A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2023-03-27","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":81},{"nctId":"NCT04821284","phase":"PHASE1, PHASE2","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Flemming Forsberg","startDate":"2021-12-06","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":120},{"nctId":"NCT05482893","phase":"PHASE1, PHASE2","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2023-03-15","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)","enrollment":258},{"nctId":"NCT03484299","phase":"PHASE1","title":"Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"University of Louisville","startDate":"2018-05-30","conditions":"Pancreas Cancer","enrollment":20},{"nctId":"NCT07043270","phase":"PHASE2","title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-09-29","conditions":"Pancreas Adenocarcinoma","enrollment":35},{"nctId":"NCT04481204","phase":"PHASE2","title":"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-18","conditions":"Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma","enrollment":105},{"nctId":"NCT04888312","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alligator Bioscience AB","startDate":"2021-09-17","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":94},{"nctId":"NCT03563248","phase":"PHASE2","title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-08-10","conditions":"Pancreatic Cancer","enrollment":168},{"nctId":"NCT04325425","phase":"PHASE2","title":"Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-09-01","conditions":"Neuroendocrine Carcinoma","enrollment":218},{"nctId":"NCT06896188","phase":"PHASE1","title":"9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2025-09-22","conditions":"Pancreatic Adenocarcinoma","enrollment":12},{"nctId":"NCT07096362","phase":"PHASE2","title":"Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-09-09","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":50},{"nctId":"NCT05132244","phase":"NA","title":"Monitoring and Managing Glucose Levels in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2024-04-16","conditions":"Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia","enrollment":50},{"nctId":"NCT05610163","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-12-08","conditions":"Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":783},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT03724994","phase":"","title":"Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer","status":"COMPLETED","sponsor":"Lund University","startDate":"2018-10-30","conditions":"Periampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer","enrollment":201},{"nctId":"NCT06249321","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Pancreatic Cancer, Radiotherapy","enrollment":30},{"nctId":"NCT04141995","phase":"PHASE2","title":"FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2021-02-12","conditions":"Pancreas Cancer, Adenocarcinoma of the Pancreas","enrollment":11},{"nctId":"NCT06149689","phase":"PHASE2","title":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-10","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT03806309","phase":"PHASE2","title":"OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-04-10","conditions":"Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer","enrollment":106},{"nctId":"NCT05132504","phase":"PHASE2","title":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2022-08-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06813976","phase":"PHASE3","title":"PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2025-07-02","conditions":"Ampullary Adenocarcinoma","enrollment":294},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT06057831","phase":"PHASE2","title":"PET/MRI in Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2026-05","conditions":"Rectal Cancer","enrollment":40},{"nctId":"NCT02979483","phase":"NA","title":"Management of Symptomatic Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2016-12-19","conditions":"Pancreas, Management Supportive Care Program","enrollment":110},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT06046794","phase":"NA","title":"Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients","status":"RECRUITING","sponsor":"Institut Paoli-Calmettes","startDate":"2024-05-23","conditions":"Cancer Of Pancreas","enrollment":100},{"nctId":"NCT04084496","phase":"PHASE2","title":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-09-01","conditions":"Pancreatic Cancer","enrollment":80},{"nctId":"NCT06897644","phase":"PHASE3","title":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-03-27","conditions":"Pancreatic Adenocarcinoma Advanced or Metastatic","enrollment":340},{"nctId":"NCT04276857","phase":"NA","title":"Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-05-01","conditions":"Locally Advanced Pancreatic Cancer, Irreversible Electroporation","enrollment":27},{"nctId":"NCT03033927","phase":"","title":"Predicting Effective Therapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01-24","conditions":"Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":74},{"nctId":"NCT03750669","phase":"PHASE3","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-20","conditions":"Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy","enrollment":324},{"nctId":"NCT02896907","phase":"EARLY_PHASE1","title":"Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2016-10-18","conditions":"Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":8},{"nctId":"NCT03984214","phase":"PHASE3","title":"Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2019-12-16","conditions":"Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic","enrollment":109},{"nctId":"NCT05298722","phase":"NA","title":"Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-12-12","conditions":"Pancreatic Cancer","enrollment":45},{"nctId":"NCT06892054","phase":"PHASE2","title":"Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2025-06-30","conditions":"Pancreatic Adenocarcinoma","enrollment":15},{"nctId":"NCT06278454","phase":"PHASE1","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2024-01-09","conditions":"Unresectable Pancreatic Cancer","enrollment":58},{"nctId":"NCT06743386","phase":"NA","title":"Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )","status":"NOT_YET_RECRUITING","sponsor":"French Society of Digestive Endoscopy","startDate":"2025-04","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT06868693","phase":"","title":"Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer","status":"NOT_YET_RECRUITING","sponsor":"Azienda Unita Sanitaria Locale di Piacenza","startDate":"2026-01-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer Stage II, Neoadjuvant Therapy","enrollment":240},{"nctId":"NCT06844422","phase":"PHASE1, PHASE2","title":"Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02-08","conditions":"Pancreatic Cancer","enrollment":37},{"nctId":"NCT05257993","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-03-30","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06812728","phase":"PHASE2","title":"Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients","status":"RECRUITING","sponsor":"Menoufia University","startDate":"2025-01-25","conditions":"Rectum Cancer","enrollment":100},{"nctId":"NCT03795311","phase":"PHASE1, PHASE2","title":"Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2018-11-07","conditions":"Colorectal Cancer","enrollment":32},{"nctId":"NCT03899636","phase":"PHASE3","title":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Angiodynamics, Inc.","startDate":"2021-02-23","conditions":"Stage III Pancreatic Cancer","enrollment":528},{"nctId":"NCT01821612","phase":"EARLY_PHASE1","title":"Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-05-29","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":23},{"nctId":"NCT05546411","phase":"PHASE2","title":"A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer","status":"TERMINATED","sponsor":"Kimberly Perez, MD","startDate":"2023-01-06","conditions":"Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":8},{"nctId":"NCT05121038","phase":"PHASE1, PHASE2","title":"CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anup Kasi","startDate":"2021-10-20","conditions":"Colon Cancer, Pancreas Cancer, Digestive Cancer","enrollment":50},{"nctId":"NCT06714604","phase":"PHASE3","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2023-10-18","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer","enrollment":432},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT04423731","phase":"","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-01-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":251},{"nctId":"NCT06681038","phase":"PHASE2","title":"Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)","status":"NOT_YET_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2025-02","conditions":"Peritoneal Metastases from Colorectal Cancer","enrollment":114},{"nctId":"NCT03941093","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2019-05-10","conditions":"Pancreatic Cancer Non-resectable","enrollment":284},{"nctId":"NCT05462496","phase":"PHASE2","title":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-03-16","conditions":"Pancreatic Cancer","enrollment":25},{"nctId":"NCT04927780","phase":"PHASE3","title":"Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2021-09-07","conditions":"Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":378},{"nctId":"NCT03879109","phase":"PHASE3","title":"Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2019-07-08","conditions":"Rectal Cancer","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Folinic Acid, 5-FU, Oxaliplatin, Irinotecan"],"phase":"phase_2","status":"active","brandName":"FOLFIRINOX chemotherapy","genericName":"FOLFIRINOX chemotherapy","companyName":"OncoSil Medical Limited","companyId":"oncosil-medical-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFIRINOX is a chemotherapy regimen used to treat pancreatic cancer. It consists of a combination of four drugs, but the specific mechanism of action is not provided in the given facts, only that it acts as a granulocyte colony-stimulating factor receptor agonist.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}